Trials / Terminated
TerminatedNCT01998399
Ticagrelor in Severe Community Acquired Pneumonia
Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Gordon Bernard · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the drug ticagrelor will be an effective treatment for patients with severe community acquired pneumonia. The primary objective is to reduce all-cause mortality in the ticagrelor group compared to the placebo group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ticagrelor | Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days |
| DRUG | Placebo | Placebo 180 mg loading dose followed by 90 mg BID for 90 days. |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2013-11-28
- Last updated
- 2017-12-11
- Results posted
- 2016-03-11
Locations
26 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01998399. Inclusion in this directory is not an endorsement.